MedTrace Logo

Study of PCC1 for Skin Rejuvenation

NCT06641869 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-08-11

No results posted yet for this study

Summary

This clinical trial will assess the efficacy of PCC1 for skin rejuvenation. The primary objective is to determine whether these interventions enhance skin barrier function, reduce wrinkles, and improve skin texture and radiance over a 12-week period. The study will involve healthy participants applying the treatments and undergoing assessments at baseline, 6 weeks, and 12 weeks. Secondary objectives include evaluating the safety and tolerability of PCC1, with any adverse effects closely monitored during the trial.

Conditions

  • Skin Rejuvenation

Interventions

DIETARY_SUPPLEMENT

procyanidin C1

Proprietarily extracted procyanidin C1

DIETARY_SUPPLEMENT

Placebo

Placebo

DIETARY_SUPPLEMENT

PCC1 complex

5 mg of procyanidin C1. Frequency: Administered once daily. Duration: 12 weeks.

Sponsors & Collaborators

  • Express Rx, Inc

    lead INDUSTRY

Principal Investigators

  • Emilia Loewe · Express Rx, Inc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-10
Primary Completion
2024-02-23
Completion
2024-08-10

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06641869 on ClinicalTrials.gov